New Zealand markets closed

OCGN Jan 2023 7.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.25000.0000 (0.00%)
As of 03:43PM EDT. Market open.
Full screen
Loading interactive chart…
  • Motley Fool

    Where Will Ocugen Be in 1 Year?

    The past 18 months have been a roller coaster for Ocugen (NASDAQ: OCGN). Shares of the biotech company skyrocketed in early 2021 after it announced an agreement with India-based Bharat Biotech. The deal stipulated that Ocugen would hold the right to commercialize the Covaxin coronavirus vaccine, which was originally developed by Bharat Biotech, in the U.S. and Canada.

  • Motley Fool

    Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript

    With me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide a financial update. Earlier this morning, we issued a press release, including a business update and first-quarter financial results for 2022.

  • Zacks

    Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates

    Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?